Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 20/20 | 1.00 |
| ▸ | GRM4 | Q14833 | 20/20 | 1.00 |
| ▸ | GRM6 | O15303 | 13/20 | 0.66 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4102325 | 0.86 | GRM8 (1.00) | GRM8GRM4GRM6GRM7 | |
| SCHEMBL8238927 | 0.80 | GRM4 (1.00) | GRM8GRM4GRM6GRM7 | |
| SCHEMBL10000470 | 0.80 | GRM4 (1.00) | GRM8GRM4GRM6GRM7 | |
| SCHEMBL8242043 | 0.79 | GRM8 (0.89) | GRM8GRM4GRM6GRM7 | |
| SCHEMBL4260547 | 0.79 | GRM8 (1.00) | GRM8GRM4GRM6GRM7 | |
| SCHEMBL4091107 | 0.79 | GRM8 (1.00) | GRM8GRM4GRM6GRM7 | |
| SCHEMBL10027439 | 0.79 | GRM8 (1.00) | GRM8GRM4GRM6GRM7 | |
| SCHEMBL4095288 | 0.79 | GRM4 (1.00) | GRM8GRM4GRM6GRM7 | |
| SCHEMBL4084361 | 0.78 | GRM8 (1.00) | GRM8GRM4GRM6GRM7 | |
| SCHEMBL4085091 | 0.78 | GRM8 (1.00) | GRM8GRM4GRM6GRM7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170813-A1 | Hypophosphorous Acid Derivatives and their Therapeutical Applications | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2009-07-02 | — | — | US | disclosed |
| US-20090170813-A1 | Hypophosphorous Acid Derivatives and their Therapeutical Applications | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2009-07-02 | — | — | US | disclosed |
| US-20090170813-A1 | Hypophosphorous Acid Derivatives and their Therapeutical Applications | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2009-07-02 | — | — | US | disclosed |
| WO-2007052169-A2 | HYPOPHOSPHOROUS ACID DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170813-A1 | Hypophosphorous Acid Derivatives and their Therapeutical Applications | P4HA1, CYP2R1, EGLN3 | GRM8 1667/4885GRM4 1497/4885GRM6 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.